因塞特 INCY 深 沪
已收盘 08-21 16:00:00 美东时间
127.81
+0.590
+0.46%
华盛通- 最 高129.92
- 今 开126.45
- 成交量 136.74万股
- 最 低 125.60
- 昨 收 127.22
- 总市值 259.07亿
- 52周最高 132.60
- 市盈率 静 19.94
- 换手率 0.67%
- 52周最低 81.09
- 委 比 67.03%
- 总股本 2.03亿
- 历史最高 153.15
- 量 比 1.00
- 振 幅 3.40%
- 历史最低 11.76
- 每 手 1
- 风险率 10.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion. Buying $1000 In INCY: If an investor had bought $1000 of INCY stock 20 years ago, it ...
08-21 07:30
美股盘后 | Nordson大升7.45%，BitMine Immersion Technologies大升7.16%
Nordson大升7.45%；BitMine Immersion Technologies大升7.16%；Strategy上升3.99%
08-20 06:10
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
08-18 00:11
Incyte Earnings Call: Growth Surges, Costs Climb
Incyte (($INCY)) has held its Q2 earnings call. Read on for the main highlights...
08-15 08:23
Regeneron, Tenet leads top healthcare companies with highest earnings beats
As corporate earnings season progresses, investors are tracking sector performance metrics to gauge underlying healthcare demand and corporate efficiency. For the healthcare sector, spanning critical ...
08-12 18:54
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays raised the price target for Darling Ingredients Inc (NYSE:DAR) from $62 to $65. Barclays analyst Ther...
08-03 20:16
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
08-03 18:18
